



Unlocking precision in immune profiling: sensitivity, accuracy, and versatility across sample types

Yue Yun, PhD


Senior Director, NGS R&D

For Research Use Only. Not for use in diagnostic procedures.

© 2025 Takara Bio Inc. All rights reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Additional product, intellectual property, and restricted use information is available at takarabio.com.

that's
GOOD
science!®

Takara Bio: core capabilities



NGS

Spatial genomics

PCR, qPCR, RT-PCR

Cloning

Nucleic acid purification


Gene delivery

Functional genomics

Protein expression & purification

OEM

Decoding the immune system through repertoire sequencing



Created with BioRender.com

Applications of TCR and BCR repertoire sequencing



T-cell receptors (TCRs)

- Study tumor-infiltrating T cells in cancer immunotherapy
- Monitor immune response to viral infection
- Investigate safety and clonal diversity of T cells used in T-cell/CAR-T/adoptive transfer therapies



B-cell receptors (BCRs)

- Understand antibody response to pathogens
- Identify B-cell clones associated with autoimmune disease symptoms or severity
- Develop new antibody therapies

Takara Bio offers diverse solutions for immune profiling

Multiplexing

- Unique dual indexes (UDIs)
- Sequence 384 samples in a single run

Sequencing flexibility

- Full length sequencing (2 x 300 PE)
- CDR3 sequencing only (2 x 150 PE)

Captures isotypes

- **BCR:** IgA/D/E/G/M (heavy chain)
IgK/L (light chain)
- **TCR:** TCR α , TCR β

Sensitivity

- Low-abundant clonotypes
- Low-expressing TCRs and BCRs

Adaptable input


- 1 ng–1 μ g RNA
- Direct cell input (TCR kits)

Various sample types

- RNA, direct cell inputs (e.g., T cells), PBMCs, whole blood, bone marrow, lymph nodes, FFPE & fragmented RNA

Accuracy

- Unique molecular identifiers (UMIs)
- Error correction
- Confident clonotype calling



Takara Bio's advantages in NGS immune profiling



Unlocking precision
in immune profiling



Accuracy

Unbiased amplification

Reproducibility

Full-length reads



Versatility

Bulk or single-cell

Fresh/frozen or FFPE

Clinical research samples



Scalability

100,000 cells per run

384 unique dual indexes

Superior
sensitivity

Obtain accuracy from your immune profiling studies



Accuracy

Unbiased amplification

Reproducibility

Full-length reads

Sensitivity

Spike-in control study (FDA)



Accuracy

Unbiased amplification

Reproducibility



Full-length reads

Sensitivity

Evaluating bias in BCR repertoire profiling with SMART-Seq® Human BCR (with UMIs)

FDA consortium spike-in control study:

- Used mRNA from nine different cell lines as spike-in controls (each at a known concentration: 1–35% of the master mix)
- Spiked in control mRNA into a series of pooled PBMC dilutions



Unbiased amplification


Reproducibility

Sensitivity


Thanks to Dr. Wenming Xiao at the Food & Drug Administration for leading this study that brought together assay developers, sequencing platform providers, and bioinformatics solution providers.

Unbiased amplification across spike-in cell lines

Expression abundance (droplet digital PCR)




Observed cell line proportions (NGS)



Unbiased amplification


Observed proportions are the same (by ranking) as expected, demonstrating **unbiased amplification**

Cell line proportions post normalization




Reproducible performance across a wide mRNA input range

SMART-Seq Human BCR (with UMIs) performs consistently at low and high inputs




Clonotype frequencies correlate between technical replicates




Reproducible at
low inputs (25 ng)

Reproducible at
high inputs (500 ng)



Reproducibility

UMIs enhance immune profiling accuracy and quantification



Adding UMIs allows you to:



Eliminate duplicates created during PCR and sequencing



Correct errors




Achieve quantitative accuracy



Avoid over-sequencing



Precise quantification of low-abundance clonotypes



Ratio of detected spiked-in BCR clonotypes versus total reads:

- Showed strong correlation with the corresponding spike-in concentration
- Indicates **unbiased detection**

25 ng RNA input: $R^2 = 0.910\text{--}0.969$

100 ng RNA input: $R^2 = 0.940\text{--}0.967$

500 ng RNA input: $R^2 = 0.961\text{--}0.974$



Sensitivity

The power of full-length V(D)J sequencing (SARS-CoV-2 study)



Accuracy

Unbiased amplification

Reproducibility

Full-length reads

Sensitivity

Tracking immune expansion after Covid-19 vaccination

Project workflow

1

PBMC samples collected at four time points

2

RNA extraction with NucleoSpin RNA kit

3

Library preparation with SMART-Seq Human BCR (with UMIs) kit


4

Sequencing with Illumina® NextSeq® 2000


5

Data analysis with Cogent™ NGS Immune Profiler

Sample collection



A closer look at individual #1—clonotype abundance at four time points



Critical sequences are missed with CDR3 only libraries

A closer look at the hyper expansion of clonotypes in individual #1 after second vaccination

Species	Gene	Allele	AccNum	Domain label	Functionality	FR1-IMGT (1-26) CDR1-IMGT (27-38) FR2-IMGT (39-55) CDR2-IMGT (56-65) FR3-IMGT (66-104) CDR3-IMGT (105-117)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																		
						A (1-15)	B (16-26)	BC (27-38)	C (39-46)	C' (47-55)	C'C'' (56-65)	C'' (66-74)	D (75-84)	E (85-96)	F (97-104)	FG																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																								
						1 10 15 16 23 26 27 38 39 41 46 47 55 56 65 66 74 75 84 85 89 96 97 104 105																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																		

Full-length V(D)J libraries uncover missed clonotypes

A closer look at the hyper expansion of clonotypes in individual #1 after second vaccination

Species	Gene	Allele	AccNum	Domain label	Functionality	FR1-IMGT (1-26)	CDR1-IMGT (27-38)	FR2-IMGT (39-55)	CDR2-IMGT (56-65)	FR3-IMGT (66-104)	CDR3-IMGT (105-117)			
						A (1-15)	B (16-26)	C (39-46)	C' (47-55)	C'' (66-74)	D (75-84)	E (85-96)	F (97-104)	FG
Homsap	IGHV3-33	IGHV3-33*01	AB019439	VH	F	1 10 15 16 23 26 27	38	39 41 46 47 55	56 65	66 74 75 84 85 89 96 97 104 105				
Homsap	IGHV3-48	IGHV3-48*01	M99675	VH	F	1 10 15 16 23 26 27	38	39 41 46 47 55	56 65	66 74 75 84 85 89 96 97 104 105				

With a full-length BCR library, **IGHV3-33** was found to be most abundant

Takara Bio's full-length V(D)J sequencing captures the difference between the IGHV3-33 and IGHV3-48 genes in the CDR2 region



Full-length reads

Obtaining versatility across different sample types



Bulk or single-cell


Fresh/frozen or FFPE

Clinical research samples

Sensitivity

Technology—Coming soon!

MaxiSeq™ Human FFPE TCR+BCR (with UMIs) kit



Versatility

Bulk or single-cell

Fresh/frozen or FFPE

Clinical research samples

Sensitivity



Unlocking immune biomarkers from vital archived samples

FFPE samples are **challenging**




Starting with DNA

Advantages:

- Captures full repertoire—whether actively expressed or not
- More stable—archived FFPE samples may be used

Disadvantages:

- No isotype information
- Single copy per cell—high input required




Starting with RNA

Advantages:

- Reflect active expression
- Identify different isoforms
- Multiple copies per cell—lower inputs can be used

Disadvantages:

- Less stable—degraded and fragmented RNA



Fresh/frozen or FFPE

Coming soon!

MaxiSeq Human FFPE TCR+BCR (with UMIs)



FFPE RNA immune profiling
with UMI-based accuracy

↔ Supports input range of 200 ng–1 µg

↓ Works with low RIN and DV200 values



Detects all human

|| TCR chains (TCR α , β , γ , δ)


Y BCR chains (IgA, D, E, G, M, K, L)




Sequences CDR3 with UMI-powered accuracy



Includes free, user-friendly analytical tools




Fresh/frozen or FFPE




MaxiSeq—reliable solution for immune profiling from highly degraded FFPE RNA samples

Degraded RNA sample A
RIN: 2.8; DV200: 54%; TILs: medium

Sensitive detection




Reproducible detection




Degraded RNA sample B
RIN: 3.0; DV200: 50%; TILs: high


Sensitive detection



Reproducible detection



Degraded RNA samples with varying TIL content: successfully processed with high reproducibility using MaxiSeq chemistry



Fresh/frozen or FFPE


TIL = tumor infiltrating lymphocytes

MaxiSeq—reliable detection of TCRs in highly degraded RNA isolated from renal cell carcinoma FFPE samples

Renal cell carcinoma sample 1

RIN: 1.9; DV200: 42%; TILs: low


Reproducible detection




Renal cell carcinoma sample 2

RIN: 1.2; DV200: 34%; TILs: high

Reproducible detection



Libraries successfully prepared with FFPE samples with varying degrees of RNA degradation




The clonotypes identified depends on the tumor-infiltrating lymphocyte content in the sample



Fresh/frozen or FFPE

Leukemia study *(in collaboration with FDA, NIH, and Illumina)*




Versatility

Bulk or single-cell

Fresh/frozen or FFPE


Clinical research samples

Sensitivity



Hairy cell leukemia (HCL) arises from B cells

HCL is a rare B-cell malignancy found in 2% of leukemia cases




HCL arises from mature B cells with a restricted BCR repertoire

Hairy cells have hairy cytoplasmic projections

Goal: Identify biomarkers in a cohort of HCL samples to understand how the BCR repertoire changes over the course of treatment


Immunoglobulin heavy chain (V) gene sequences identify and track residual leukemic cells

This study is ongoing, so we will focus on one individual here



Clinical research samples


Tracking clonal proportions before and after treatment



Treatment alters the distribution of clonotype proportions in a subset of samples, highlighting **dynamic changes in the BCR immune repertoire**

Clonotype group



- Rare (>0 and $\leq 1 \times 10^{-5}$)
- Small ($>1 \times 10^{-5}$ and $\leq 1 \times 10^{-4}$)
- Medium ($>1 \times 10^{-4}$ and ≤ 0.001)
- Large (>0.001 and ≤ 0.01)
- Hyperexpanded (>0.01 and ≤ 1)



Clinical research samples

Dynamic shift in V and J gene usage over the course of treatment in individual 49

Selected genes



Clinical research samples

Before treatment



Single-cell workflows can be scaled up to 100,000 cells per run



Scalability


100,000 cells per run

384 unique dual indexes

Sensitivity

Technology

Shasta™ Total RNA-Seq Kit




Scalability

100,000 cells per run

384 unique dual indexes

Sensitivity


Shasta Total RNA-Seq Kit: a high-throughput, full gene-body coverage workflow



Created with BioRender.com



Detect more genes by increasing sequencing depth using the Shasta Total RNA-Seq Kit




Sequencing saturation not observed until read depth exceeds 5×10^5 reads per cell



100,000 cells per run

UMAP analysis allows detection of cell types in the Shasta Total RNA-Seq library




Total cells in this run: 99,851

- T cells
- B cells
- Natural killer cells
- Macrophages
- Classical monocytes
- Plasmacytoid dendritic cells
- Myeloid dendritic cells
- Progenitor cells
- Platelets



100,000 cells per run

TCR and BCR clonotypes detected in the Shasta Total RNA-Seq library



Shasta Total RNA-Seq Kit provides a wealth of data:

- High-quality scRNA-seq library
- Full gene-body coverage
- Detailed UMAP to identify cell types
- Valuable TCR and BCR clonotype detection

Made at [SankeyMATIC.com](https://sankeymatic.com)

Takara Bio's high-quality portfolio provides accurate, versatile, and scalable solutions for immune profiling




Accuracy

Unbiased amplification

Reproducibility

Full-length reads

Sensitivity



Versatility

Bulk or single-cell

Fresh/frozen or FFPE

Clinical research samples

Sensitivity




Scalability

100,000 cells per run

384 unique dual indexes

Sensitivity

Takara Bio's immune profiling NGS product portfolio— an end-to-end solution



Created with BioRender.com

SMART[®] technology outperforms in immune profiling

A study systematically compared the results of nine commercial and academic TCR-seq methods, including:


- Takara Bio's **Switching Mechanism at 5' end of RNA Template (SMART)** technology
- Rapid amplification of cDNA ends (RACE)

Takara Bio's SMART TCR technology outperformed in both **sensitivity and reliability**

Rank values are between 2 (best) and 7 (worst)



Human CD4⁺ CD25⁻ cells



DNA-seq

None of the multiplex PCR methods can detect TCR α chains

RNA-seq

Barennes, P. et al. Benchmarking of T cell receptor repertoire profiling methods reveals large systematic biases. *Nature Biotechnology* 39(2), (2021)

Created with BioRender.com

TR chain	Method	Replicability	Reliability	Sensitivity	Cost per sample (\$)	Controls and standards	Format type	FASTQ data availability
TRA	RACE-1	7	4	4	~230	—	Lab protocol	Yes
	RACE-1_U	4	5	4	~230	UMI	Lab protocol	Yes
	RACE-2	5	4	5	230–280	—	Service or kit	Yes
	RACE-2_U	4	5	5	230–280	UMI	Service or kit	Yes
	RACE-3	3	2	3	~150	—	Kit	Yes
TRB	RACE-4	5	6	4	~150	—	Lab protocol	Yes
	RACE-5	2	3	3	~300	—	Lab protocol	Yes
	mPCR-1	3	3	3	~300–550	Synthetic TCRs	Service or kit	No
	mPCR-2	6	7	7	~25	—	Lab protocol	Yes
	mPCR-3	5	5	3	~300–550	—	Service or kit	Yes
	RACE-1	6	5	4	~230	—	Lab protocol	Yes
	RACE-1_U	4	6	5	~230	UMI	Lab protocol	Yes
	RACE-2	6	6	6	230–280	—	Service or kit	Yes
	RACE-2_U	6	6	7	230–280	UMI	Service or kit	Yes
	RACE-3	2	2	3	~150	—	Kit	Yes
	RACE-4	3	5	4	~150	—	Lab protocol	Yes

Takara Bio SMART TCR

Multiplex PCR with gDNA

Takara Bio SMART TCR

Over 1,000 publications in high-impact journals

nature medicine



Article

<https://doi.org/10.1038/s41591-024-03334-7>

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial

nature communications



Article

<https://doi.org/10.1038/s41467-024-49209-w>

KSHV infection of B cells primes protective T cell responses in humanized mice

Sample publications

- Barennes, P. et al. Benchmarking of T cell receptor repertoire profiling methods reveals large systematic biases. *Nat. Biotechnol.* **39**, 236–245 (2020).
- Caduff, N. et al. KSHV infection of B cells primes protective T cell responses in humanized mice. *Nat. Commun.* **15**, 1–13 (2024) under a [CC BY 4.0](#) license.
- Chen, R. et al. NUDCD3 deficiency disrupts V(D)J recombination to cause SCID and Omenn syndrome. *Sci. Immunol.* **9**, (2024).
- Lopez, J. et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. *Nat. Med.* **31**, 152–164 (2025) under a [CC BY 4.0](#) license.
- Ogega, C. O. et al. Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance. *Immunity* **57**, 890-903.e6 (2024).

Generating more meaningful immunological insights


MORE Cells
Biomarkers
Discoveries
Breakthroughs

Visit us at **Booth #543** to learn more
and meet with our experts!

Takara Bio immune profiling solutions



Highest sensitivity
for low-input samples



Versatility across
sample types



Accuracy powered by
UMIs with easy and free
analytical tools



Discovery of rare
TCR/BCR biomarkers

Acknowledgements

We would like to thank the following collaborators for their vital contributions

- Wenming Xiao at the Food & Drug Administration (FDA) for leading the spike-in control study that brought together assay developers, sequencing platform providers, and bioinformatics solution providers
- Wenming Xiao at the FDA, Evgeny Arons at the National Institutes of Health, and Robin Bombardi at Illumina for helping with the leukemia study

Thank You!



that's
GOOD
science!®